Key result
CYP2C19*2 carrier status was associated with significantly increased residual platelet aggregation after a 600 mg clopidogrel loading dose compared with noncarriers (OR 4.6; 95% CI 2.5-8.7; P<0.0001).
Why the study?
Does CYP2C19*2 genotype combined with nongenetic risk factors predict high residual platelet aggregation after a 600 mg clopidogrel loading dose in patients undergoing PCI?
Observational (n=237)
Does CYP2C19*2 genotype combined with nongenetic risk factors predict high residual platelet aggregation after a 600 mg clopidogrel loading dose in patients undergoing PCI?
Odds Ratio: 4.6 (95% CI 2.5–8.7)
p-value: p=<0.0001
Combining CYP2C19*2 genotype with clinical risk factors significantly improves the prediction of poor responsiveness to a clopidogrel loading dose in patients undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Supports adding CYP2C19*2 to clinical models for predicting clopidogrel response in PCI; hypothesis-generating for outcome trials.
Geisler et al. (2008) conducted an observational in Coronary artery disease (n=237). CYP2C19*2 carrier status vs. Noncarriers was evaluated on Increased residual platelet aggregation (RPA) (OR 4.6, 95% CI 2.5-8.7, p=<0.0001). CYP2C19*2 carrier status was associated with significantly increased residual platelet aggregation after a 600 mg clopidogrel loading dose compared with noncarriers (OR 4.6; 95% CI 2.5-8.7; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: